联合免疫,安全可行——评区域MSLN CAR-T细胞联合抗PD-1药物在治疗恶性胸膜疾病患者中的应用

Safety and Feasibility:Evaluation of the Application of Regional MSLN CAR⁃T⁃Cell Therapy in Patients With Malignant Pleural Disease,in Combination With the Anti⁃PD⁃1 Agent Pembrolizumab

1文献来源Adusumilli PS,Zauderer MG,Rivière I,et al.A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease,in combination with the anti-PD-1 agent pembrolizumab[J].Cancer Discov,2021,11(11):2748-2763.2证据水平1b。